Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Development of Poloxamer-Based Solid Suppository Containing Diclofenac Sodium

폴록사머를 이용한 디클로페낙 고형 좌제의 개발

  • Published : 2004.04.20
Download PDF
⟨ Previous Next ⟩

Abstract

To develop a poloxamer-based solid suppository with poloxamer mixtures, the melting points of various formulations composed of P 124 and P 188 were investigated. To investigate the effect of poloxamer to the dissolution ad dissolution mechanism of diclofenac sodium from the suppository the dissolution of diclofenac sodium delivered by the poloxamer-based suppository was performed. Furthermore, to investigate the mucoadhesive property of the poloxamer-based sold suppository, the identification test in the rectum was carried out after its rectal administration in rats. The poloxamer mixtures composed of P 124 and P 188 were homogeneous. Ver small amounts of P 188 affected the melting points of poloxamer mixtures. In particular, the poloxamer mixture [P 124/P 188 (97/3%)] with the melting point of about $32^{\circ}C$ was a sold for at room temperature and instantly melted at physiological temperature. Furthermore, very small amounts of P 188 in the poloxamer-based suppository hardly affected the dissolution rates of diclofenac sodium from the suppository. Dissolution mechanism analysis showed the dissolution of diclofenac sodium was proportional to the time. At 4 h after administration, the blue colo of poloxamer-based suppository [diclofenac sodium/poloxamer mixture (2.5/97.5%)] with the P 124/ P 188 ratio of (97/3%) and blue lake in the rectum was faded. However, the position of suppository in the rectum did not significantly change with time. Thus, it retained in thε rectum for at least 4 h. Our results indicated that the poloxamer-based sold suppository with P 124 and P 188 would be a candidate of rectal dosage form for diclofenac sodium.

Keywords

References

  1. C.H. Huang, T. Tokumura, Y. Machida and T. Nagai, Formulation of double- layered suppository for prolonged stay in lower rectum, Yakuzaigaku, 47, 42-48 (1987)
  2. A.H. Burstein, K.M. Fisher, M.L. McPherson and C.A. Roby, Absorption of phenytoin from rectal suppositories formulated with a polyethylene glycol base, Pharmacotherapy, 20, 562-567 (2000) https://doi.org/10.1592/phco.20.6.562.35157
  3. C.J. Eboka, R.S. Okor, J.O. Akerele, S.O. and Aigbavboa, Kinetics of absorption and elimination of ofloxacin in humans after oral and rectal administrations, J. Clin. Pharm.Ther., 22, 217-220 (1997) https://doi.org/10.1046/j.1365-2710.1997.95075950.x
  4. A. Nagatomi, M. Mishima, O. Tsuzuki, S. Ohdo and S. Higuchi, Utility of a rectal suppository containing the antiepileptic drug zonisamide, BioI. Pharm. Bull., 20, 892-896 (1997) https://doi.org/10.1248/bpb.20.892
  5. C.K. Kim, S.W. Lee, H.G. Choi, M.K. Lee, Z.G. Gao and I.S. Kim, Trials of in-situ gelling and mucoadhesive acetaminophen liquid suppository in human subjects, Int. J. Pharm., 174, 201-207 (1998) https://doi.org/10.1016/S0378-5173(98)00258-0
  6. H.G. Choi, J.H. Jung, J.M. Ryu, S.J. Yoon, Y.K. Oh and C.K. Kim, Development of in-situ gelling and mucoadhesive acetaminophen liquid suppository, Int. J. Pharm., 165, 33-44 (1998) https://doi.org/10.1016/S0378-5173(97)00386-4
  7. C. Abhaham, Poloxamer gel systems with gelling temperatures higher than room temperature, Canadian Patent, 1072413 (1994)
  8. M.O. Yun, H.G. Choi, J.H. Jung and C.K. Kim, Development of thermoreversible insulin liquid suppository with sodium salicylate, Int. J. Pharm., 189, 137-145 (1999) https://doi.org/10.1016/S0378-5173(99)00227-6
  9. H.G. Choi, Y.K. Oh and C.K. Kim, In-situ gelling and mucoadhesive liquid suppository containing acetaminophen: enhanced bioavailability, Int. J. Pharm., 165, 23-32 (1998) https://doi.org/10.1016/S0378-5173(97)00385-2
  10. S. Miyazaki, T. Nakamura, C. Yokouchi and M. Tanaka, Effect of pluronic gels on the rectal absorption of indomethacin in rabbits, Chem. Pharm. Bull., 35, 1243-1248 (1987) https://doi.org/10.1248/cpb.35.1243
  11. A Schneeweis and C.C. Muller-Goymann, In vivo and in vitro diclofenac sodium evaluation after rectal application of soft gelatine capsules enabling application induced transformation (AlT) into a semisolid system of liquid crystals (SSLC) for controlled release, Pharm. Res., 14, 1726-1729 (1997) https://doi.org/10.1023/A:1012127829032
  12. K. Nakanishi, T. Masukawa, M. Masadaand and T. Nadai, Improvement of the rectal bioavailability of latamoxef sodium by adjuvants following administration of a suppository, BioI. Pharm. Bull., 17, 1496-1500 (1994) https://doi.org/10.1248/bpb.17.1496
  13. H.G. Choi, B.J. Lee, C. Yong, J.D. Rhee, J.H. Han, M.K. Lee, K.M. Park and C.K. Kim, Terfenadine--cyclodextrin inclusion complex with the anti-histaminic activity enhancement, Drug Dev. Ind. Pharm., 27, 1259-1263 (2001) https://doi.org/10.1081/DDC-100107250
  14. M. Iwata K. Takayama, Y. Takahashi, Y. Obata, Y. Machida, T. Nagai and S. Shirotake, Effect of temperature on drug release and drug absorption in mixed type diclofenac sodium suppositories, Yakugaku Zasshi (Japan), 119, 170-177 (1999) https://doi.org/10.1248/yakushi1947.119.2_170
  15. S. Ramakrishna, N.W. Fadnavis and P.V. Diwan, Comparative pharmacokinetic evaluation of compressed suppositories of diclofenac sodium in humans, Arzneimittelforschung, 46, 175177 (1996)
  16. N.A. Peppas, Analysis of Fickian and non-Fickian drug from release polymers. Pharm. Acta Helv., 60, 110-111 (1985)